Web Stats Provided By Google Analytics

Friday, August 4, 2017

mAb glucagon receptor blocker suitable for further development

The glucagon receptor blocker REGN1193, a fully human monoclonal antibody, seems safe and tolerable enough for further development, according to a study published online July 28 in Diabetes, Obesity and Metabolism . Ana Kostic, Ph.D., from Regeneron Pharmaceuticals in Tarrytown, N.Y., and colleagues gave healthy men and women single ascending doses of REGN1193 ranging from 0.05 mg/kg to 0.6 mg/kg or placebo intravenously.

No comments:

Post a Comment

Popular Tarrytown Roundup Posts